Table 4. Risk factors for longer duration of hospitalization in children hospitalized with Mycoplasma pneumoniae infection, Ohio, USA, 2015–2019*.
| Risk factor | Univariate analysis |
Multivariable analysis |
|||
|---|---|---|---|---|---|
| RR (95% CI) | p value | aRR (95% CI) | p value | ||
| Female sex | 0.85 (0.63–1.15) | 0.2852 | |||
| Age, y | 0.98 (0.95–1.01) | 0.2213 | |||
| Underlying condition | 1.25 (0.92–1.71) | 0.1592 | |||
| Any previous visit | 0.83 (0.58–1.16) | 0.2734 | |||
| Macrolide resistance | 2.91 (1.56–5.44) | 0.0008 | 2.04 (0.97–4.32) | 0.061 | |
| Abnormal respiratory examination | 1.14 (0.77–1.7) | 0.5103 | |||
| Previous treatment with antimicrobial drugs | 0.94 (0.69–1.27) | 0.6882 | |||
| Previous nonmacrolide antimicrobial drugs | 0.97 (0.71–1.31) | 0.8204 | |||
| Positive viral test | 0.96 (0.69–1.34) | 0.8122 | |||
| MRMp and positive viral test | 1.67 (0.51–5.44) | 0.3946 | |||
*Bold type indicates statistical significance. aRR, adjusted RR; MRMp, macrolide-resistant Mycoplasma pneumoniae; RR, relative risk.